Novo Nordisk A/S ADR
(NVO)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 09-2024 | 06-2024 | 03-2024 | 12-2023 | 09-2023 | |
| Sales | 10,511,240 | 9,821,058 | 9,514,814 | 9,526,155 | 8,574,726 |
| Cost of Goods | 1,666,799 | 1,482,538 | 1,443,770 | 1,448,192 | 1,418,098 |
| Gross Profit | 8,844,442 | 8,338,520 | 8,071,045 | 8,077,962 | 7,156,628 |
| Operating Expenses | 3,859,878 | 4,596,782 | 3,435,037 | 4,207,256 | 3,227,428 |
| Operating Income | 4,985,363 | 3,742,276 | 4,636,778 | 3,870,901 | 3,929,298 |
| Interest Expense | 121,015 | 225,397 | 301,974 | -260,988 | 316,528 |
| Other Income | 203,854 | 138,529 | 312,457 | -138,534 | 484,428 |
| Pre-tax Income | 5,068,202 | 3,655,408 | 4,647,261 | 3,993,355 | 4,097,198 |
| Income Tax | 1,044,034 | 762,193 | 948,002 | 818,001 | 815,410 |
| Net Income Continuous | 4,024,167 | 2,893,215 | 3,699,259 | 3,175,355 | 3,281,788 |
| Net Income | $4,024,167 | $2,893,215 | $3,699,259 | $3,175,355 | $3,281,788 |
| EPS Basic Total Ops | 0.90 | 0.65 | 0.83 | 0.71 | 0.73 |
| EPS Basic Continuous Ops | 0.90 | 0.65 | 0.83 | 0.71 | 0.73 |
| EPS Diluted Total Ops | 0.90 | 0.65 | 0.83 | 0.71 | 0.73 |
| EPS Diluted Continuous Ops | 0.90 | 0.65 | 0.83 | 0.71 | 0.73 |
| EPS Diluted Before Non-Recurring Items | 0.90 | 0.65 | 0.83 | N/A | N/A |
| EBITDA(a) | $5,338,726 | $5,014,821 | $5,061,056 | $4,300,201 | $4,297,558 |